DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Urelumab
Urelumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
RT+IO Therapy in NSCLC Draft 4 Clinical Cancer Research 1
ESCMID Online Lecture Library @ by Author
Timmerman Et Al-2020-Urelumab
Immune Checkpoint Inhibition in DLBCL Immunotherapy: “The Cure Is Inside Us”
Table S1. Medications Searched in Institutional Database Query Immune Checkpoint Inhibitors Additional Immune Modulators Atezol
Immunfarmakológia Immunfarmakológia
The Two Tontti Tudiul Lui Hi Ha Unit
A Review of Current Biologics Targeting OX40, 4-1BB, CD27, and GITR
WO 2018/027204 Al 08 February 2018 (08.02.2018) W !P O PCT
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Ep 3178848 A1
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Outlook for Global Medicines Through 2021 Balancing Cost and Value
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Top View
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
2018 Medicines in Development for Cancer
WO 2017/095848 Al 8 June 2017 (08.06.2017) W P O P C T
(INN) for Biological and Biotechnological Substances
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody Neil H
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Omdirigert Skriverdokument for Eksternt Skrivebord
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Identifying Major Immune Subsets of GI Tumors for Clinical
Harnessing the Innate Immune System and Local Immunological Microenvironment to Treat Colorectal Cancer
Meeting the Potential of Immunotherapy: New Targets Provide Rational Combinations Jane De Lartigue, Phd
812 Urelumab (Anti-CD137 Agonist)
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
CD137 As an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
Listes De DCI Proposées N'implique Aucune Recommandation En Vue De L'utilisation De La Substance Correspondante En Médecine Ou En Pharmacie
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
(INN) for Biological and Biotechnological Substances
Profiling of Patients with Glioma Reveals the Dominant Immunosuppressive Axis Is Refractory to Immune Function Restoration
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
Checkpoint Inhibitors and Other Novel Immunotherapies for Advanced Renal Cell Carcinoma